{"id":193592,"date":"2021-07-13T08:05:45","date_gmt":"2021-07-13T08:05:45","guid":{"rendered":"https:\/\/pr.asianetpakistan.com\/?p=76287"},"modified":"2021-07-13T08:05:45","modified_gmt":"2021-07-13T08:05:45","slug":"inspirata-partners-with-kings-health-partners-ecmc-and-guys-and-st-thomas-nhs-foundation-trust-to-evaluate-the-application-of-ai-automation-in-matching-patients-with-cancer","status":"publish","type":"post","link":"https:\/\/taiwannewswire.com\/inspirata-partners-with-kings-health-partners-ecmc-and-guys-and-st-thomas-nhs-foundation-trust-to-evaluate-the-application-of-ai-automation-in-matching-patients-with-cancer\/","title":{"rendered":"Inspirata Partners with King\u2019s Health Partners ECMC and Guy\u2019s and St Thomas\u2019 NHS Foundation Trust to Evaluate the Application of AI Automation in Matching Patients with Cancer to Early Phase Clinical Trials"},"content":{"rendered":"

London, United Kingdom, July 13, 2021 (GLOBE NEWSWIRE) — Cancer informatics and digital pathology provider\u00a0Inspirata\u00a0announced today that King\u2019s Health Partners ECMC and Guy\u2019s and St Thomas\u2019 NHS Foundation Trust will pilot its\u00a0Trial Navigator\u2122\u00a0software as part of an evaluation the\u00a0organisations\u00a0are conducting into how artificial\u00a0intelligence based\u00a0automation can improve the identification and efficiency of matching patients with cancer to early phase clinical trials. Trial Navigator\u2019s introduction as part of a pilot evaluation within the Cancer Early Phase Trials Unit will see\u00a0Inspirata\u00a0collaborate with both King\u2019s Health Partners and the Experimental Cancer Medicine Centre (ECMC) Network\u00a0Programme\u00a0Office.<\/p>\n

Delays in candidate identification and the absence of real-time visibility of open studies introduces a risk that patients miss out on trials for which they could have ultimately proved eligible. By applying oncology-specific natural language processing (NLP) to interrogate both the patient\u2019s individual medical reports and potential trial eligibility criteria, this project will explore the extent to which Trial Navigator can help to improve bottlenecks in both identifying and matching patients to relevant clinical trials.<\/p>\n

\u201cAt the Cancer Centre at Guy\u2019s, we\u2019re constantly striving to get the best possible outcomes for our patients, and sometimes that means providing them with the opportunity to\u00a0enrol\u00a0on trials of new cancer drugs when conventional treatments have been unsuccessful. AI technology offers the potential to better match our patients to available trials, but we need to evaluate them first to prove that they can deliver on their promise,\u201d\u00a0says Danny\u00a0Ruta, Clinical Artificial Intelligence Lead, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust.\u00a0\u201cWe hope that the intelligent automation afforded by Trial Navigator will prove to be an effective solution for identifying greater numbers of our eligible cancer patient population for clinical trials.\u201d<\/p>\n

\u201cOur patients are looking to us for assurances that all possible options and avenues associated with their care have been thoroughly evaluated,\u201d\u00a0says Debashis Sarker, Reader in Experimental Oncology in the School of Cancer and Pharmaceutical Studies of King\u2019s College London, and Honorary Consultant in Medical Oncology at Guy\u2019s and St Thomas\u2019 NHS Foundation Trust.\u00a0\u201cI am hugely attracted to any toolset which serves to augment my own understanding of the different trial options available so that I can impart this confidence and where applicable, see more patients obtain prompt access to potential new treatments in a\u00a0more timely\u00a0manner\u201d.<\/p>\n

While building on an underlying oncology NLP engine that has already been successfully deployed at over 400+ hospitals and cancer\u00a0centres\u00a0worldwide, Trial Navigator has been purposely designed to improve clinical trial\u00a0matching by supporting both the clinician at the point of care, and trial coordinators with patient identification. Trial Navigator can also be deployed to perform instantaneous lookups against any relevant trial database.<\/p>\n

\u201cDigital technology will play a key role in ensuring that the UK remains one of the best places in the world to conduct experimental cancer medicine studies, so that our UK patients get access to novel therapies at the earliest opportunity. We are excited to support a project that seeks to aid clinicians in the complex and time-consuming task of matching patients to suitable trials,\u201d\u00a0says Michelle Mitchell, Chief Executive of Cancer Research UK, which co-funds the ECMC network.<\/p>\n

\u201cWe could not be more excited nor proud to work with Guy\u2019s and St Thomas\u2019, Kings Health Partners and ECMC on this project,\u201d\u00a0says Oenone\u00a0Duroe, General Manager,\u00a0Inspirata\u00a0Europe.\u00a0\u201cWe look forward to collaborating closely with the team to validate the efficacy of AI in a clinical trial matching context, and by drawing on insights derived, support equivalent Trial Navigator engagements within the National Health Service.\u201d\u00a0<\/b><\/p>\n

About Inspirata Europe Ltd.<\/b><\/p>\n

Inspirata Europe helps patients fighting cancer\u2014and the clinicians they trust\u2014to make every moment matter. Our comprehensive cancer informatics solutions bring disparate data together throughout the entire cancer care journey to drive informed decisions that improve survivorship.<\/p>\n

Inspirata has assembled the most advanced and proven technologies to address the complex challenges of delivering cancer care and conducting ground-breaking research. We combine leading digital pathology solutions with automated cancer registry solutions, comprehensive cancer informatics and advanced patient engagement tools to bring users the broadest oncology informatics platform available globally. For more information, please visit\u00a0www.inspirata.com<\/a>\u00a0or contact\u00a0info@inspirata.com<\/a>.<\/p>\n

For further information about Inspirata, please contact:<\/strong><\/p>\n

Graeme Collins
\nInspirata Europe, Ltd.
\nTel: +44 (0)330 330 9038
\nE-mail:\u00a0gcollins@inspirata.com<\/a><\/p>\n

Attachments<\/strong><\/p>\n